Price
$176.86+17.24%Social Signal Score
Analyst Ratings
34 analystsRevenue
$4.98B+54.22%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas E. Polen Jr.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 72,000
- Beta
- 0.28
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.11
Financials
Revenue
$4.98B+54.2%Net Income
$377.00M+1884.2%EBITDA
$686.00M+82.0%Free Cash Flow
$509.00M+24.1%EPS (diluted)
$1.37+1422.2%Shares Outstanding (diluted)
275.16M+26.3%Operating Expenses
$1.52BCash & Debt
$709.00MReturn of Capital
$3.13BRevenue by Segment (annual)
$21.84BDividend per Share
$1.05Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $21.84B | $1.68B | $5.84 |
| 2024 | $20.18B | $1.71B | $5.88 |
| 2023 | $19.37B | $1.48B | $4.97 |
| 2022 | $18.87B | $1.78B | $5.93 |
| 2021 | $19.13B | $2.09B | $6.92 |
| 2020 | $16.07B | $874.00M | $2.75 |
| 2019 | $17.29B | $1.23B | $3.96 |
| 2018 | $15.98B | $311.00M | $0.62 |
| 2017 | $12.09B | $1.10B | $4.70 |
| 2016 | $12.48B | $976.00M | $4.59 |
| 2015 | $10.28B | $695.00M | $3.43 |
| 2014 | $8.45B | $1.19B | $6.13 |
| 2013 | $8.05B | $1.29B | $6.63 |
| 2012 | $7.71B | $1.17B | $5.59 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BDX's reported EPS growth of 0.3% a year over 13 years.
- EPS in 5 years
- $5.94
- Implied price
- $148.57
- Return from $176.80
- -3.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $73.87 — -58.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -9.7% | -19.5% | -16.0% | -13.0% | -10.4% | -8.1% |
| -4.7% | -15.0% | -11.4% | -8.2% | -5.5% | -3.0% |
| 0.3% | -10.6% | -6.7% | -3.4% | -0.5% | 2.1% |
| 5.3% | -6.1% | -2.1% | 1.4% | 4.5% | 7.2% |
| 10.3% | -1.7% | 2.6% | 6.2% | 9.4% | 12.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
158+215.29%Social Signal Score
Mentions (17)
- News (Marketaux)gurufocus.com·1h ago·Positive
Becton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supply Production On October 06, 2026, Becton Dickinson & [+320 characters]
View source ↗ - News (RSS)seekingalpha·2h ago·Neutral
Trump: Becton Dickinson agrees to invest $3B in US manufacturing, including $1B+ in Nebraska
View source ↗ - News (RSS)investing·3h ago·Neutral
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing
View source ↗ - Newsreuters.com·8h ago·Neutral
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing American medical technology company Becton Dickinson has agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, President Donald Trump said on Monday in a post on the Truth Social website.
View source ↗ - Newszacks.com·4d ago·Positive
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
View source ↗ - Newszacks.com·7d ago·Neutral
Here's Why You Should Retain BDX Stock in Your Portfolio for Now Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
View source ↗ - Newsprnewswire.com·14d ago·Neutral
Arthur Hu to Join BD as Chief Information and Digital Officer FRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30.
View source ↗ - Newsprnewswire.com·22d ago·Neutral
…s, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medic…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·40d ago·Neutral
… to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.
View source ↗ - Newsprnewswire.com·40d ago·Neutral
BD to Present at Wells Fargo 21st Annual Healthcare Conference FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.
View source ↗ - Newszacks.com·46d ago·Negative
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
View source ↗ - Newsprnewswire.com·49d ago·Neutral
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
View source ↗ - Newszacks.com·53d ago·Neutral
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion e
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Becton, Dickinson and Company Q3 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $4.06 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$3.23 vs $3.14beat
- Thu, May 7$2.90 vs $2.78beat
- Mon, Feb 9$2.91 vs $2.21beat
- Thu, Nov 6$3.96 vs $3.92beat
- Thu, Aug 7$3.68 vs $3.40beat
- Thu, May 1$3.35 vs $3.28beat
Estimates and results for BDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDX officers and directors.
- Bought
- —
- Sold
- $2.7m
0 trades
20 trades
- Feld Michaelsold
- Feld Michaelsold
- Polen Thomas E Jrsold
- Goette Rolandsold
- Feld Michaelsold
- Feld Michaelsold
- Garrison Michael Davidsold
- Garrison Michael Davidsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 19, 2026 (29d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (20d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 18, 2025 (36d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (40d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 6, 2024 (2d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (297d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 18, 2024 (25d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (15d later)Buy$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Mar 15, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Feb 20, 2024 (40d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.